Market | Rising stars are rising, the CDK4/6 inhibitor market is getting bigger and bigger

CDK4/6, namely cyclin-dependent kinases 4 and 6, is a key regulator of the cell division cycle.

A large number of clinical research data show that CDK4/6 inhibitors can significantly improve the progression-free survival (PFS), overall survival (OS) and quality of life of HR+/HER2- breast cancer patients.

At present, four CDK4/6 inhibitors have been approved globally, namely Pfizer’s Ibrance (palbociclib, piperacillin), Novartis’s Kisqali (Ribociclib, Ribociclib), Eli Lilly’s Verzenio (Abemaciclib, abeciclib) and G1 Therapeutics’ Cosela (trilaciclib).

The above three CDK4/6 inhibitors approved for the treatment of HR+/HER2- breast cancer have not been studied head-to-head, and it is impossible to compare which has the best treatment effect.

In addition, Verzenio is the first CDK4/6 inhibitor to be shown to statistically significantly reduce the risk of cancer recurrence in HR+/HER2-high-risk early breast cancer patients.

According to the financial reports of various companies, Ibrance has dazzled sales by virtue of its first-mover advantage.

CDK4/6 inhibitors, as the rising anti-cancer "magic drug" in recent years, are rapidly changing the treatment pattern of HR+/HER2- advanced breast cancer, effectively overcoming or delaying the emergence of endocrine resistance, and striving for more for advanced patients Survival time.